-
China’s MoC Lists US Firms PVH and Illumina as Unreliable Entities
•
China’s Ministry of Commerce (MoC) has released a list of unreliable entities, including US firms Philips-Van-Heusen (PVH) and Illumina, Inc. (NASDAQ: ILMN). These companies were cited for violating normal market trading principles, interrupting normal transactions with Chinese enterprises, taking discriminatory measures against Chinese firms, and seriously damaging the legitimate rights…
-
Roche Reports 7% Growth in Full-Year Sales, Strength in Pharmaceuticals
•
Swiss pharmaceutical giant Roche (SWX: ROG) released its Q4 and full-year 2024 financials, reporting a strong year with 7% year-on-year (YOY) growth across the group at constant exchange rates. Total sales reached CHF 60.495 billion ($66.34 billion), while overall group revenues were CHF 62.395 billion ($68.42 billion), also up 7%.…
-
Sanofi Reports Strong Q4 Growth, Plans EUR 5 Billion Share Buyback
•
French pharmaceutical giant Sanofi (NASDAQ: SNY) reported a strong fourth-quarter performance with 10.3% year-on-year (YOY) growth in net sales in constant currency terms, reaching EUR 10.564 billion ($11 billion). The growth was driven by a 56.5% increase in new pharma launches, a 16% rise in sales of Dupixent (dupilumab), and…
-
Xtalpi Partners with JW Pharmaceutical to Enhance Drug Discovery with AI
•
Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., a global leader in AI-powered drug discovery, has announced a multi-million RMB strategic partnership with South Korea’s leading pharmaceutical company, JW Pharmaceutical (KRX: 001060). The collaboration aims to integrate AI and automation into drug discovery, enhancing JW Pharmaceutical’s development efficiency,…
-
DeepSeek’s AI: Transforming Drug Development and Healthcare in China
•
DeepSeek, a Chinese artificial intelligence company, is poised to make a significant impact on the pharmaceutical industry through its advanced natural language processing (NLP) and large language model (LLM) technologies. The potential applications span multiple dimensions, including data-driven research, clinical decision-making, and resource management. This analysis explores the potential impacts…
-
MediLink Therapeutics’ YL217 Receives FDA IND Clearance for Novel ADC Targeting Gastrointestinal Cancers
•
MediLink Therapeutics, a clinical-stage biotech company, announced today that its internally developed antibody-drug conjugate (ADC), YL217, has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). YL217 is the 11th ADC candidate to enter clinical development based on MediLink’s proprietary TMALIN® platform. YL217: A Novel…
-
AbbVie’s 2024 Revenue Grows Despite Humira Decline, Skyrizi and Rinvoq Surge
•
US-based pharmaceutical giant AbbVie (NYSE: ABBV) reported its 2024 financial results on January 31, with total revenue reaching $56.33 billion, a 3.7% increase from the previous year. The company’s R&D investment surged 66.7% to $12.79 billion, reflecting a strategic focus on innovation and new product development. Business Segment PerformanceIn 2024,…
-
PegBio’s Lead Product PB-119 Clears HKEX Hearing for Type 2 Diabetes and Obesity Treatment
•
On January 28, 2025, the Hong Kong Stock Exchange (HKEX) website showed that PegBio Co., Ltd., a Suzhou-based specialist in endocrine metabolism, has successfully passed the HKEX hearing. China International Capital Corporation (CICC) acted as the sole sponsor. Company OverviewPegBio was established in 2008 as a biotechnology company focused on…
-
Roche Reports 7% Revenue Growth in 2024, Driven by Oncology and Ophthalmology
•
Roche (SWX: ROG) released its 2024 annual financial report on January 30, showing a 7% year-on-year increase in revenue to CHF 60.495 billion (USD 68.892 billion), calculated based on the average exchange rate of 2024 (1 CHF = USD 1.1388). The company’s R&D expenditure reached CHF 13.042 billion (USD 14.852…
-
DeepSeek Enhances Biopharma IND and NDA Processes with AI
•
In the regulatory submissions for Investigational New Drug (IND) and New Drug Application (NDA) in the biopharmaceutical sector, DeepSeek, as an AI technology tool or service platform, can enhance the efficiency and compliance of the application process through the following means: Data Management and Analysis Document Automation and Compliance Support…
-
Enhertu Approved by FDA for HR-Positive, HER2-Low Breast Cancer
•
Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) jointly announced that their co-developed antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received FDA approval for the treatment of unresectable or metastatic hormone receptor (HR) positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2 ultra-low (IHC 0 with membrane staining) breast…
-
Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model
•
On January 27, 2025, the Hong Kong Stock Exchange (HKEX) website displayed that Suzhou Vigonvita Life Sciences Co., Ltd submitted an application for listing on the HKEX, with CITIC Securities as the sponsor. Company Overview and MissionThe prospectus shows that Vigonvita Bio, established in 2013, is an integrated biopharmaceutical company…
-
CStone Pharmaceuticals Partners with SteinCares for Sugemalimab Commercialization in Latin America
•
CStone Pharmaceuticals (HKG: 2616), a China – based biopharmaceutical company focused on oncology drug development, announced on January 27 a strategic commercialization partnership with SteinCares, a leading pharmaceutical company in the Latin American market. Under the licensing and commercialization agreement, SteinCares will obtain the rights to commercialize sugemalimab in 10…
-
MicroPort’s Fireliums Receives NMPA Approval for Coronary Bifurcation Stenosis Treatment
•
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its coronary rapamycin drug balloon dilation catheter, Fireliums, for dilation treatment of primary coronary artery bifurcation stenosis. This approval marks a significant milestone in the commercialization of this…
-
MicroPort’s TomaHawk Intravascular Shock Wave Therapy Device Approved by NMPA
•
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its TomaHawk intravascular shock wave therapy device, disposable coronary intravascular shock wave catheter (TomaHawk coronary intravascular shock wave catheter system). This approval marks a significant milestone in the…
-
FDA Clears sBLA for Eisai and Biogen’s Leqembi Maintenance Dosing
•
Partners Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have announced that the US Food and Drug Administration (FDA) has cleared their supplemental Biologics License Application (sBLA) for once every four weeks Leqembi (lecanemab-irmb) intravenous (IV) maintenance dosing. The drug is approved in the US for the treatment…
-
Jiangsu Yuyue Partners with Inogen for International Distribution and R&D
•
China-based Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (SHE: 002223) has struck a partnership with US medtech company Inogen, Inc. (NASDAQ: INGN). The alliance aims to leverage the respective brand and product influence of both companies to work together on international distribution business, trademark licensing and distribution business, joint…
-
Guangzhou Innogen’s Efsubaglutide Alfa Approved by NMPA for Type 2 Diabetes
•
China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd, a biopharma focused on metabolic diseases, has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its efsubaglutide alfa to treat type 2 diabetes (T2D). This approval marks a significant milestone in the development and commercialization of efsubaglutide alfa, positioning…
-
MSD and Eisai’s Keytruda/Lenvima Combo Shows Promise in Gastroesophageal Cancer Study
•
Partners Merck, Sharp & Dohme (MSD, NYSE: MRK) and Eisai (TYO: 4523) have announced the latest results from the Phase III LEAP-015 study, which evaluated the combination of MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) with Eisai’s kinase inhibitor Lenvima (lenvatinib) plus chemotherapy. The study focused on the first-line treatment of patients…
-
NHSA Targets Low-Volume Drugs in National Reimbursement List
•
The National Healthcare Security Administration (NHSA) in China has released a list of 131 drugs that are included in the National Reimbursement Drug List (NRDL) but have seen little trade volume. The move aims to ensure the basic medication needs of insured patients by monitoring the production and supply of…
